Drugs / CTLA4-Ig
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01773707 | Mar 2013 → Dec 2021 | glucose intolerance, type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00505375 | Feb 2008 → May 2012 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTLA-4 Ig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00505375 ↗ |
| Action | Inhibit | “CTLA4-Ig (Abatacept) inhibits a crucial stimulatory pathway in the activation of T cells.” NCT00505375 ↗ |
| Route | Intravenous | “The experimental group will receive intravenous infusions of CTLA-4 Ig.” NCT00505375 ↗ |